文献速递造血干细胞移植与细胞治疗贫血与红细胞疾病

UM171扩增脐带血移植与其他移植物来源相比结局改善:真实世界证据

Improved outcomes of UM171-expanded cord blood transplantation compared with other graft sources: real-world evidence.
PubMed 文献 · Blood Adv · 2023-01-01

该分析回顾性比较了UM171扩增脐带血移植1-2期试验(22例)与CIBMTR数据库中未处理脐带血移植(67例)及匹配无关供者移植(70例)的结果。UM171扩增脐带血组较脐带血对照1年及2年非复发死亡率更低,2年无进展生存率及无GVHD无复发生存率更高,1年总生存率改善;较匹配无关供者对照1年及2年非复发死亡率更低,2年无进展生存率及1年、2年无GVHD无复发生存率更高,且3-4级急性GVHD和慢性GVHD更少。研究提示UM171扩增脐带血受者可能获益于更低的非复发死亡率和更高的无GVHD无复发生存率。

要点

  • UM171扩增脐带血组较脐带血对照1年及2年非复发死亡率更低。
  • UM171扩增脐带血组较匹配无关供者对照1年及2年非复发死亡率更低。
  • UM171扩增脐带血受者较匹配无关供者移植物受者3-4级急性GVHD和慢性GVHD更少。

核心结论

  • 与脐带血和匹配无关供者异基因造血干细胞移植的真实世界证据相比,本研究提示UM171扩增脐带血受者可能获益于更低的非复发死亡率和更高的无GVHD无复发生存率。

研究设计与样本

  • 回顾性比较1-2期试验中UM171扩增脐带血移植受者与CIBMTR数据库中未处理脐带血及匹配无关供者移植受者的结果。
  • 共纳入CIBMTR来源137例(脐带血67例,匹配无关供者70例)及UM171扩增脐带血22例。
  • 患者按既往异基因造血干细胞移植次数、疾病及细化疾病风险指数直接匹配,并进一步按年龄、合并症指数和体能状态进行倾向评分匹配。

主要发现

  • UM171扩增脐带血组较脐带血对照1年及2年非复发死亡率更低,2年无进展生存率和无GVHD无复发生存率更高,1年总生存率改善。
  • UM171扩增脐带血组较匹配无关供者对照1年及2年非复发死亡率更低,2年无进展生存率更高,1年及2年无GVHD无复发生存率更高。
  • UM171扩增脐带血受者较匹配无关供者移植物受者3-4级急性GVHD和慢性GVHD更少。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cord blood (CB) transplantation is hampered by low cell dose and high nonrelapse mortality (NRM). A phase 1-2 trial of UM171-expanded CB transplants demonstrated safety and favorable preliminary efficacy. The aim of the current analysis was to retrospectively compare results of the phase 1-2 trial with those after unmanipulated CB and matched-unrelated donor (MUD) transplants. Data from recipients of CB and MUD transplants were obtained from the Center for International Blood and Marrow Transplant Research (CIBMTR) database. Patients were directly matched for the number of previous allogeneic hematopoietic stem cell transplants (alloHCT), disease and refined Disease Risk Index. Patients were further matched by propensity score for age, comorbidity index, and performance status. Primary end points included NRM, progression-free survival (PFS), overall survival (OS), and graft-versus-host disease (GVHD)-free relapse-free survival (GRFS) at 1 and 2 years after alloHCT. Overall, 137 patients from CIBMTR (67 CB, 70 MUD) and 22 with UM171-expanded CB were included. NRM at 1 and 2 years was lower, PFS and GRFS at 2 years and OS at 1 year were improved for UM171-expanded CBs compared with CB controls. Compared with MUD controls, UM171 recipients had lower 1- and 2-year NRM, higher 2-year PFS, and higher 1- and 2-year GRFS. Furthermore, UM171-expanded CB recipients experienced less grades 3-4 acute GVHD and chronic GVHD compared with MUD graft recipients. Compared with real-world evidence with CB and MUD alloHCT, this study suggests that UM171-expanded CB recipients may benefit from lower NRM and higher GRFS. This trial was registered at www.clinicaltrials.gov as #NCT02668315.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Cohen S, Bambace N, Ahmad I, et al. Improved outcomes of UM171-expanded cord blood transplantation compared with other graft sources: real-world evidence. Blood Adv. 2023. PMID: 37467030. doi:10.1182/bloodadvances.2023010599

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。